CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...

PHILADELPHIA (WPVI) -- The Food & Drug Administration has approved a new drug for Alzheimer's Disease. It's the first in nearly twenty years but it comes with controversy and some experts advised ...

NEW YORK, Aug. 29, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iqlik, for ...

Cognition Therapeutics Inc. CGTX shares jumped 30% to $1.43 in pre-market trading on Wednesday after the company announced FDA confirmation of its Phase 3 trial design for Alzheimer’s drug Zervimesine ...

(Reuters) -The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

In many cases, it's not until memory problems start creeping up that most people learn they have Alzheimer's disease. By then, the disease may already be progressing, leaving limited options for ...

Eli Lilly LLY0.62%increase; green up pointing triangle on Friday said the Food and Drug Administration would hold an advisory committee meeting on its proposed Alzheimer’s disease drug donanemab, ...

Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease drug sodium oligomannate, also known as GV-971, according to online records ...